Eurocine Vaccines has Completed Dosing of its Quadrivalent Influenza Vaccine Candidate, Immunose(TM) FLU, in the Second Clinical Study
Eurocine Vaccines has Completed Dosing of its Quadrivalent Influenza Vaccine Candidate, Immunose(TM) FLU, in the Second Clinical Study
STOCKHOLM, May 18. 2018 /PRNewswire/ -- This week, dosing was completed according to plan in the second clinical study with Immunose(TM) FLU, developed with the aim to become a modern and effective nasal influenza vaccine.
- In the perspective of this year's severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer.
-The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine in this segment. This, without loosing sight of our vision, to offer the first nasal influenza vaccine for children younger than 2 years, adds Hans Arwidsson, CEO of Eurocine Vaccines.
The strategy behind this present study, and its design, was presented in a previous news release dated February 7th, 2018 and can be read at;
The progress of the study can also be followed at; https://clinicaltrials.gov
Results are expected second half of 2018.
CONTACT:
Hans Arwidsson,
Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46-70-634-0171
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
http://mb.cision.com/Main/11552/2523738/843685.pdf Read as pdf
View original content:http://www.prnewswire.com/news-releases/eurocine-vaccines-has-completed-dosing-of-its-quadrivalent-influenza-vaccine-candidate-immunose-flu-in-the-second-clinical-study-300650891.html
SOURCE Eurocine Vaccines
